ATE488249T1 - Immunologisch bedeutende herpes-simplex-virus- antigene und verfahren für ihre verwendung - Google Patents

Immunologisch bedeutende herpes-simplex-virus- antigene und verfahren für ihre verwendung

Info

Publication number
ATE488249T1
ATE488249T1 AT02748276T AT02748276T ATE488249T1 AT E488249 T1 ATE488249 T1 AT E488249T1 AT 02748276 T AT02748276 T AT 02748276T AT 02748276 T AT02748276 T AT 02748276T AT E488249 T1 ATE488249 T1 AT E488249T1
Authority
AT
Austria
Prior art keywords
hsv
herpes simplex
simplex virus
amino acids
fragment
Prior art date
Application number
AT02748276T
Other languages
English (en)
Inventor
David Koelle
Nancy Hosken
Christine Posavad
Hongbo Chen
Patrick Mcgowan
Original Assignee
Univ Washington
Corixa Corp
Hutchinson Fred Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington, Corixa Corp, Hutchinson Fred Cancer Res filed Critical Univ Washington
Application granted granted Critical
Publication of ATE488249T1 publication Critical patent/ATE488249T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5154Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16611Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT02748276T 2001-07-31 2002-07-31 Immunologisch bedeutende herpes-simplex-virus- antigene und verfahren für ihre verwendung ATE488249T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30892301P 2001-07-31 2001-07-31
US30942801P 2001-08-01 2001-08-01
PCT/US2002/024306 WO2003011893A2 (en) 2001-07-31 2002-07-31 Immunologically significant herpes simplex virus antigens and methods for using same

Publications (1)

Publication Number Publication Date
ATE488249T1 true ATE488249T1 (de) 2010-12-15

Family

ID=26976523

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02748276T ATE488249T1 (de) 2001-07-31 2002-07-31 Immunologisch bedeutende herpes-simplex-virus- antigene und verfahren für ihre verwendung

Country Status (8)

Country Link
US (2) US6814969B2 (de)
EP (2) EP1420821B8 (de)
JP (1) JP4519461B2 (de)
AT (1) ATE488249T1 (de)
AU (1) AU2002317604A1 (de)
CA (1) CA2454750C (de)
DE (1) DE60238330D1 (de)
WO (1) WO2003011893A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1523582T3 (da) 2002-07-18 2009-03-02 Univ Washington Hurtig, effektiv rensning af HSV-specifikke T-lymfocytter samt HSV-antigener identificeret derved
AU2004274430A1 (en) 2003-09-12 2005-03-31 Antigenics, Inc. Vaccine for treatment and prevention of herpes simplex virus infection
EP2460815B1 (de) 2005-04-15 2015-06-03 Human Matrix Sciences, LLC Pflanzliche, elastinbindende Proteinliganden und deren Verwendung
CA2523032A1 (en) 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
JP5872755B2 (ja) 2006-07-20 2016-03-01 バイカル インコーポレイテッド 抗hsv−2ワクチン接種のための組成物および方法
EP2185145A1 (de) 2007-04-04 2010-05-19 Board of Trustees of the University of Arkansas Nichtspezifische verzögerte überempfindlichkeitsantwort zur behandlung von infektionen mit dem herpes simplex virus
CN106310293A (zh) 2007-09-27 2017-01-11 免疫疫苗技术有限公司 在包括连续疏水相的载体中的脂质体在体内输送多核苷酸中的应用
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
AU2009253780B2 (en) * 2008-06-05 2014-08-14 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
US8460674B2 (en) 2009-02-07 2013-06-11 University Of Washington HSV-1 epitopes and methods for using same
US9044447B2 (en) 2009-04-03 2015-06-02 University Of Washington Antigenic peptide of HSV-2 and methods for using same
MY159500A (en) * 2009-05-22 2017-01-13 Genocea Biosciences Inc Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
US20130224236A1 (en) * 2010-11-03 2013-08-29 University Of Washington Hsv-1 epitopes and methods for using same
WO2012074881A2 (en) 2010-11-24 2012-06-07 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
EP2763698B1 (de) 2011-10-06 2020-12-02 ImmunoVaccine Technologies Inc. Liposomzusammensetzungen mit einem adjuvans zur aktivierung oder steigerung der aktivität von tlr2 und verwendungen davon
WO2013078299A1 (en) 2011-11-23 2013-05-30 Genocea Biosciences, Inc. Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
RS57420B1 (sr) 2012-05-16 2018-09-28 Immune Design Corp Vakcine za hsv-2
CA2976268C (en) 2015-02-26 2021-07-06 Squarex, Llc Non-specific delayed-type hypersensitivity response to treat herpes simplex virus infection
JP2019512501A (ja) * 2016-03-14 2019-05-16 レッドバイオテック・アーゲーRedbiotec Ag Hsvを処置するための手段及び方法
JP2019537555A (ja) 2016-09-28 2019-12-26 ジェノセア バイオサイエンシーズ, インコーポレイテッド ヘルペスを処置するための方法および組成物
US20200164060A1 (en) * 2017-07-21 2020-05-28 Fred Hutchinson Cancer Research Center Herpes simplex virus vaccine epitopes specifically recognized by tissue resident memory t cells
CN112710849A (zh) * 2020-12-24 2021-04-27 首都医科大学附属北京友谊医院 一种鉴定抗EBV免疫活性的ELISpot试剂盒、制备方法及应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859587A (en) 1984-06-04 1989-08-22 Institut Merieux Recombinant herpes simplex viruses, vaccines and methods
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
EP0541692B1 (de) 1990-08-02 1999-05-06 Chiron Corporation Herpes simplex virus vp16 impfstoffe
CA2090295A1 (en) 1992-02-03 1993-08-04 Anthony B. Nesburn Process for the expression of herpes simplex virus type 1 glycoprotein e and methods of use
US5426039A (en) 1993-09-08 1995-06-20 Bio-Rad Laboratories, Inc. Direct molecular cloning of primer extended DNA containing an alkane diol
JPH11510386A (ja) 1995-07-28 1999-09-14 マリー キュリー キャンサー ケア 輸送蛋白質およびそれらの使用
GB9615726D0 (en) * 1996-07-26 1996-09-04 Medical Res Council Anti-viral agent 11
EP0948508A4 (de) 1996-11-04 2001-11-07 Smithkline Beecham Corp Kodierungssequenzen vom herpes-simplex-virus typ 2
US6017735A (en) * 1997-01-23 2000-01-25 Marie Curie Cancer Care Materials and methods for intracellular transport and their uses
EP0984790A1 (de) * 1997-06-02 2000-03-15 Chiron Corporation Impfstoff gegen herpes simplex viren enthaltend vp22 und dessen verwendungen
KR20010085348A (ko) * 1998-08-07 2001-09-07 추후보정 면역능을 갖는 헤르페스 심플렉스 바이러스 항원 및 이를이용하는 방법
JP2003512305A (ja) * 1999-09-30 2003-04-02 ユニバーシティ オブ ワシントン 免疫学的に重要な単純疱疹ウイルス抗原
US6821519B2 (en) * 2000-06-29 2004-11-23 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
JP2004501663A (ja) * 2000-06-29 2004-01-22 コリクサ コーポレイション 単純疱疹ウイルス感染の診断および処置のための組成物および方法

Also Published As

Publication number Publication date
AU2002317604A1 (en) 2003-02-17
US20040241182A1 (en) 2004-12-02
EP1420821B8 (de) 2011-02-02
WO2003011893A2 (en) 2003-02-13
EP1420821A2 (de) 2004-05-26
DE60238330D1 (de) 2010-12-30
EP1420821B1 (de) 2010-11-17
JP4519461B2 (ja) 2010-08-04
WO2003011893A3 (en) 2003-09-12
EP2191845A1 (de) 2010-06-02
JP2004537308A (ja) 2004-12-16
US7037509B2 (en) 2006-05-02
US20030190324A1 (en) 2003-10-09
US6814969B2 (en) 2004-11-09
CA2454750C (en) 2012-09-18
CA2454750A1 (en) 2003-02-13
EP1420821A4 (de) 2006-08-30

Similar Documents

Publication Publication Date Title
ATE488249T1 (de) Immunologisch bedeutende herpes-simplex-virus- antigene und verfahren für ihre verwendung
MX9702714A (es) Produccion de peptidos en plantas como fusiones de proteinas con revestimiento viral.
EP2011510A3 (de) Pharmazeutische Zusammensetzungen, die immunologisch aktive Herpes simplex Virus Proteinfragmente enthalten
BG102983A (en) Extramembrane protein 106 polypeptide of moraxella catarrhalis, its gene sequence and application
ECSP064643A (es) Proteinas de fusion de glp-1
CA2111645A1 (en) Fibrinogen fragment e peptides and antibodies thereto
IL135687A0 (en) A novel human checkpoint kinase, hcds1, compositions and methods
ATE298798T1 (de) Fusionsproteine zwischen antigene aminosäuresequenzen und beta - 2- mikroglobulin
DE69233311D1 (de) Weidelgraspollen-allergen
FI930626A (fi) Proteinstruktur hos vaexttoxingelonin
DK1417222T3 (da) Isolerede polypeptider baseret på den neutraliserende epitop af p17-proteinet fra HIV egnet til vacciner samt neutraliserende anti-p17-antistoffer, der specifikt genkender nævnte neutraliserende epitop
ES2110996T3 (es) Alergeno de polen de ballico.
AU1444699A (en) Single-chain polypeptides comprising troponin i and troponin
ATE108802T1 (de) Polypeptidhemmer für virale replikation.
DE69928947D1 (de) Moraxella catarrhalis basb034 polypeptide und verwendungen davon
EA200100314A1 (ru) Пептидные фрагменты холерного экзотоксина в или энтеротоксина в в качестве адъювантов вакцины
ATE234358T1 (de) Peptide des pferdearteritisvirus, antikörper und ihre verwendung in einem diagnostischen test
AU6393990A (en) Hiv related peptides
DE69827880D1 (de) Iga1-protease fragment als trägerpeptid
WO2001070774B1 (en) Human t cell response to mhc-binding motif clusters
NZ606260A (en) Novel polypeptides involved in immune response
MY106940A (en) Allelic variants of plasmodium falciparum merozoite surface antigen.
WO2002000832A3 (fr) Nouveau polypeptide, proteine p80-coiline 8.8, et polynucleotide codant ce polypeptide

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties